The discovery and validation of novel targets are essential to fuel a healthy drug pipeline, and in vitro phenotypic assays are instrumental for delivering valid targets and promising lead molecules.

View this webinar to learn more about our in vitro assay capabilities performed in clinically-relevant cell models, where we’ll highlight key endpoints for neurodegenerative diseases such as α-synuclein aggregation, Ab toxicity and autophagy/mitophagy readouts.


  • Folkert Verkaar, PhD, Team Leader, Biology, Charles River

Related Resources

Click the link below for the other webinar in the series: